Pane wikiwiki
Merck's $400M KRAS G12D deal pushes tech transfer earlier. See what it demands of synthesis and analytical partners in biotech supply chains.
He aha ka KRAS G12D Deal a me Biotech Supply Chains i komo maoli

Ma ka 2026-09-28, Ua komo ʻo Merck i kahi ʻaelike laikini honua kūʻokoʻa me SciBrunch Therapeutics no SPR2015, he noiʻi waha KRAS G12D (ON) mea hoʻopaneʻe. Ua uku ʻo Merck $400 miliona i mua e kū'ē i ka huina waiwai kūpono o $2.13 piliona, a lawe i nā kuleana kūʻokoʻa honua e hoʻomohala, hana a kūʻai aku i ka hui (ʻO Merck & ʻO Co. hoʻokuʻu ʻana i ka lumi nūhou, 2026-09-28). He preclinical ka waiwai: he mole kalapala me ka hana antiproliferative nanomolar ma nā laina kelepona mutant, ʻaʻole i hoʻāʻo ʻia i nā kānaka.
ʻElua mau kikoʻī i hoʻonohonoho i ke kālepa. Ka mua, ʻōpio a paʻa ka mea laikini: Aia ʻo SciBrunch ma Shanghai a ua hoʻokumu ʻia i ka hopena 2024 (ʻO Merck & ʻO Co. hoʻokuʻu ʻana i ka lumi nūhou, 2026-09-28). Ka lua, E hoʻopaʻa ʻo Merck i kahi $400 miliona ma mua o ka ʻauhau, pili ana $0.13 pakahi, i kāna Q3 2026 hopena (RTTNews, 2026-09-28).

ʻO ka $1.73 biliona like ʻole ma waena o ka $400 miliona ma mua a me ka $2.13 billion headline is milestone headroom, ʻaʻole i paʻi ʻia ka papa hana uku. As hoʻokahi kālaihana kālepa loea o nā huaʻōlelo kuhikuhi, 18.8% ʻo ka huina i hoʻolaha ʻia he kālā i hana ʻia, a ua maheleia ka milestone, ʻAʻole i hōʻike ʻia ka helu aliʻi a me ke kālai ʻāina (Nūhou Molekula Liʻiliʻi, 2026-09-29).
ʻO ka moʻolelo o ka hoʻokumu ʻana i waho o ka laikini kahi ʻāpana o ka pōʻaiapili o ka ʻaelike: Ua alakaʻi mua ka pelekikena a me CEO Tao Hu i ka laikini kūʻokoʻa honua o ka papahana oncology preclinical UA022 iā AstraZeneca ma 2023, a ʻo ia a me ka mea hoʻokumu ʻo Yang Zhang mai WuXi AppTec, me Hu i hana mua ma Merck a me Amgen ma US (Nūhou Molekula Liʻiliʻi, 2026-09-29).
No ke aha he mea nui kēia hana no nā kaulahao lako biotech
ʻO kēlā $400 ʻoi aku ka maikaʻi o ka heluhelu ʻana i ka miliona ma mua o kahi ʻōlelo e pili ana i ka hoʻokūkū, ʻaʻole e pili ana i ke oʻo ʻana o ka waiwai. Revolution Medicines 'zoldonrasib (RMC-9805) aia i loko o ka Phase 1/1b i KRAS G12D-mutant paʻa maʻi koko me 2026 ʻikepili a me kahi Phase 3 ʻO ka hoʻokolohua pancreatic laina mua, a loaʻa iā ia ka inoa FDA Breakthrough Therapy i Ianuali 2026 (Nā Laʻau Kipi, 2026-01-08). ʻO ka uku ʻana i kēlā kumukūʻai no ke komo mua ʻana e hōʻike ana i ka hoʻokūkū no nā moho RAS-alanui ʻokoʻa (ʻenehana lāʻau lapaʻau, 2026-09-28).
Hoʻoneʻe kēlā hale i ka kemika, hana mua ka hana a me ka hoomalu ana. No ka mea ua loaʻa iā Merck nā kuleana hana ma ke kahua preclinical, ala synthetic, Pono paha nā ʻano analytical a me nā kikoʻī e hoʻololi ma mua o nā haʻawina mua-i-kanaka, me ka stereochemistry, ʻano hoʻohaumia a me ka mana paʻa paʻa i waena o ka hoʻohālikelike (ʻenehana lāʻau lapaʻau, 2026-09-28). Kahi e holo ai kēlā hana ʻaʻole kūlike: ʻO ka loiloi like me ka FDA ke hoʻohui nei i nā kumuwaiwai no ka nānā ʻana i nā haole, me ka Phase hou aku 1 a me nā hoʻokolohua mua (ʻenehana lāʻau lapaʻau, 2026-09-28). Lilo nā palapala hoʻoili ʻenehana cross-border i mea paʻa ola ma kahi o ka hoʻoili ʻana, ʻaʻole ma ka waiho ʻana.
ʻO ka nui ma hope o nā kuʻikahi e like me kēia he nui a piʻi. Hōʻike ʻia ʻo Vision Life Science $136 piliona ma kahi o 157 disclosed China out-licensing deals in 2025, against about $51.9 piliona a puni 94 deals in 2024, with roughly $60 billion in Q1 2026 hoʻokahi wale nō (Vision Life Sciences, paʻi ʻia 2026-06-27). Treat those as ranges: publishers define deal value differently, and the figures are disclosed totals rather than audited sums.
Three stakeholders read this differently. Large pharma sponsors gain an earlier claim on a differentiated candidate but inherit the transfer burden sooner. China-origin biotechs licensing out gain upfront capital and lose direct control of the route and method package. Synthesis and analytical partners serving both absorb the work: hoʻomohala ʻano hana, specification setting and documentation that now sit before first-in-human studies rather than after.
He aha kēia e koi ai i ka Synthesis and Analytical Partners

Hoʻokūpaʻa kahi molecular glue i kahi paʻakikī ternary ma mua o ka noho ʻana i ka ʻeke KRAS (ʻO ka loiloi Thoracic Cancer o ka hoʻolālā hoʻolālā KRAS G12D, Kekemapa 2025), no laila stereochemistry, ʻO ka ʻaoʻao haumia a me ke ʻano paʻa e lilo i mau mea hoʻohālikelike e pono e paʻa i nā pae a me nā unahi.
ʻO ka mea e hele ai i kahi pūʻolo hoʻoili ke ʻano, nā mea kuhikuhi, ka kikoʻī a me ka ʻikepili maka. ʻO ka mea hele pinepine ʻole ka ʻike tacit ma hope o lākou, ʻo ia ke kumu e hoʻomāʻona hou ai ka ʻoihana hoʻokipa I Q2(R2) Hōʻoiaʻiʻo o nā Kaʻina Hana Analytical (hope loa, Malaki 2024). Hōʻike ʻia ka hoʻoili ʻana i ke ʻano loiloi e CDMO ma $150,000 i $400,000 pākahi pākahi, me ka hana hou ana ma $20,000 i $100,000 kēlā me kēia ʻano (Drug Patent Watch CDMO kumu kūʻai benchmarking, Malaki 2026). E mālama i kēlā mau mea e like me nā mea kūʻai aku-e pili ana me ka manaʻo kūʻai kiʻekiʻe, ʻaʻole nā kumukūʻai makeke.
Ua wehewehe ʻia ka "maʻemaʻe kiʻekiʻe" i kahi faila e I Q3A(R2) Na Laau Laau Hou, kahi e noho ai nā paepae i ka PDF ma mua o ka ʻaoʻao pae. ʻO kahi palapala hōʻoia no ka nānā ʻana e hōʻike ana i hoʻokahi helu me ka ʻole o ka ʻaoʻao haumia ma hope o ia mea e ʻōlelo liʻiliʻi e pili ana i ke ola ʻana o kēlā ʻaoʻao. Ma nā kaʻina paʻakikī, Hōʻike ʻo GenScript 93.81% kūleʻa i kāna ʻikepili NeoPre (1,030 haawiia o 1,098 hoao) ma kona ʻaoʻao holomua ʻenehana. ʻO ia ka hana i ana ʻia e ka mea hoʻolako ma kāna wehewehe ponoʻī o "paʻakikī,” ʻaʻole ka helu ʻoihana.
He palapala no kā mākou hōʻike: ʻaʻohe hōʻailona ʻaoʻao ʻekolu, ʻaʻohe ʻikepili hana a ka ʻaoʻao mua i hiki ke hoʻopaʻa ʻia a ʻaʻohe noiʻi hihia mea kūʻai aku i loaʻa no kēia loiloi. ʻO ka mea ma hope iho he ʻano o nā pae hoʻohālikelike e hoʻopili ai, ʻaʻole i hōʻoia ʻia nā hopena.
Kūlana
He aha ka nīnau
He aha ke ʻano o ka pane nāwaliwali
Ka wā pōʻaiapuni
Hoʻololi maʻamau no kahi pūʻulu SAR 40-analog, a he aha ka mea e alakaʻi ai i ka ʻokoʻa?
He helu hihia maikaʻi loa me ka ʻokoʻa ʻole
ʻO ka maʻemaʻe o ka manawa mua
Kūʻē i ke ʻano kikoʻī, ana pehea, i ka nui o nā pūʻulu?
“>95% maʻemaʻe" me ka ʻole o nā kikoʻī a i ʻole ka helu pūʻulu
Hoʻohālikelike i ka haumia-profile
ʻO ka Peptide Synthesizer Pehea e hōʻike ʻia ai ka paʻa ʻana mai ka mg a i ka kg?
ʻO kahi ʻōlelo e "paʻa mau" nā profile me ka ʻole o ka ʻikepili
Ka hoʻomalu stereochemical
Wahi noiʻi neuroscience He mea koʻikoʻi nā stereocenters, Biosynthesis o ka Hormone Peptide a pehea e hoʻomaluʻia ai kēlā me kēia?
Kuhi ʻia ka ratio diastereomer me ka ʻole o ke ala a i ʻole ka palena ʻike
ʻAno-hoʻomohala hiki
Ke holo nei ka hoʻomohala ʻana me ka synthesis a ma hope paha?
ʻO ka hana analytical i ʻōlelo ʻia ma ke ʻano he kaʻawale, pae hope
ʻO ka palapala a me ke kaulahao o ka mālama
Hiki iā ʻoe ke hōʻike i nā kaha manawa, nā mea lawelawe Iwi a me na hui a me ke kumu hoʻoili no kēlā me kēia ʻāpana?
He COA me ka ʻole o ke ala ʻikepili maka ʻImi ʻApoptosis maʻi maʻi
lawelawe IP
Pehea e hoʻopaʻa ʻia ai nā mea huna kālepa ma nā wahi a me nā palena?
ʻO ka hilinaʻi ma kahi NDA wale nō, me nā mana hana ʻole Hoʻohui ʻia ʻo Peptide Hormone
ʻO nā lālani ʻelua e lawe i ke kaumaha hou aʻe no kahi papahana palena palena. Hoʻopaʻa paʻa a me nā moʻolelo paʻa ʻikepili, me nā palapala laikini e hoʻokumu ana i ke poʻo a me ka laulā, ʻO ia ka mea e lawe ai i kahi pūʻolo ma waena o kahi laikini kumu Kina a me kahi mea laikini US; Hiki i nā ʻoihana ʻaoʻao Kina ke komo i ka hoʻopaʻa inoa ʻana i ka ʻenehana hoʻopukapuka a me, no ka ʻikepili i uhi ʻia, Nā mīkini CAC (J. ʻO Chang Law e pili ana i ka ʻenehana laikini mai Kina, Ianuali 2026). ʻO ia ke alakaʻi a ka loio, ʻaʻole i hoʻopaʻa ʻia ke kikokikona hoʻoponopono. ʻO ke ala pepa GMP e pili ana i ka API e hoʻokele kaʻawale ʻia ma lalo ʻO ICH Q7 alakaʻi hoʻomaʻamaʻa hana maikaʻi no nā mea lāʻau lāʻau ikaika (hope loa, Kepakemapa 2016), a ua hoʻonohonoho ʻia ka moʻolelo hoʻomohala e haʻi ai ke ala ICH Q11 Hoʻomohala a hana ʻana i nā mea lāʻau (hope loa, Nowemapa 2012), palapala 'āina i ka CTD Module 3 pauku 3.2.S.2.2 a hiki i ka 3.2.S.2.6.
Hoʻokahi kumu kūpono e hoʻāʻo ʻia ma ke kamaʻilio ʻana: inā paha e holo ana kekahi hoa i ka hoʻomohala ʻana i ke ʻano me ka synthesis ma mua o ia. ʻO MOL Changes kekahi laʻana o kahi hoa hana i kūkulu ʻia pēlā. E nīnau i kēlā me kēia moho i ka nīnau like a hoʻohālikelike pololei i nā pane.
ʻAʻole loaʻa ka manawa pōkole o ka hoʻopōkole ʻana i ka molekala mai ka kemika wikiwiki wale nō. Mai ka hana analytical e holo like ana, he pūʻolo hoʻoili i hui ʻia ma mua o ke koho ʻana i ka moho, a me nā palapala hoʻoili ʻenehana ma waena o nā palena ʻāina hiki i kahi keʻena hoʻokipa ke hana me ke kelepona ʻole.
ʻO ke kiʻi nui a me ka mea e hana ai i kēia manawa
ʻO ke kālepa Merck i kūpono i kahi kumu ma mua o ia: preclinical-pae, ka laikini cross-border kahi e neʻe mua ai nā kuleana hana, ma mua o ka heluhelu ʻana o ka moho. ʻO ka laikini oncology preclinical mua o ka mea hoʻokumu me AstraZeneca i hahai i kēlā ʻano 2023, a me ka 2026 ʻO nā mea heluhelu KRAS G12D pae hoʻomaʻamaʻa e noho ana ma kēlā ʻaoʻao o ka arc hoʻokahi. ʻElua mau hopena e pili ana no ka mea e ʻimi ana i ka mana synthesis. Ua lilo ka mākaukau hoʻololi i mea hoʻokele ma mua o ka hoʻokele, a ʻo ka nānā ʻana e hoʻohālike ana i ke koho ʻana i ka pūnaewele i kēia manawa e pili ana i ka hōʻike ʻana i nā kumu ʻē aʻe, no ke alakaʻi FDA ma nā hana nānā haole.
ʻEhā kapuaʻi, kauoha ʻia e ka wikiwiki:
-
E nānā i kāu pūʻolo hoʻoili ma mua o ke koho ʻana i nā moho. Inā ʻaʻole i hōʻuluʻulu ʻia ka hoʻonohonoho palapala ma ia manawa, lilo ia i ke ala koʻikoʻi.
-
E hoʻomaʻamaʻa i ka hoʻāʻo ikaika i ka wā mua. ʻO ka hōʻike ʻana o ka loea ma Drug Discovery News e kau i ka hōʻoia assay ma 6 i 12 mahina, ʻoi aku ka lōʻihi ma mua o ka nui o nā papahana e hoʻolālā ai.
-
E hōʻoia i nā huaʻōlelo o ka mālama ʻana a me ka ʻikepili analytical ma mua o ka hala ʻana o ka palena laikini.. ʻOi aku ka paʻakikī o kēia mau mea ke kūkākūkā hou ma hope.
-
Hoʻolālā i ka hāʻawi kālā, mai komo. E mālama i ke kumu kūʻai a me ka manawa ma ke ʻano he laina, ʻaʻole he pilikia.
MAI:
E noʻonoʻo i kahi pākēneka hoʻomaʻemaʻe maʻemaʻe i pani no ka hoʻohālikelike ʻana i ka ʻano haumia ma waena o ka nui.
Hoʻopaneʻe ka hoʻololi ʻana i ke ʻano a hiki i ke koho ʻana i ka moho.
Inā ʻoe e loiloi ana i nā hoa pili no kahi papahana e like me kēia, e kamaʻilio me kahi loea loea e pili ana i kāu mea e pono ai e hoʻokomo.
Hōʻike: Loaʻa i ka MOL Changes kahi hoihoi pāʻoihana i nā kūlana maikaʻi peptide.
Nīnau pinepine
He aha kā Merck i kūʻai ai, a ma ke kahua hea?
Loaʻa iā Merck nā kuleana kūʻokoʻa honua e hoʻomohala, hana a kalepa SPR2015, he noiʻi waha KRAS G12D (ON) mea hoʻopaneʻe (ʻO Merck & ʻO Co. hoʻokuʻu ʻana i ka lumi nūhou, 28 Kepakemapa 2026). Ua loaʻa iā SciBrunch Therapeutics kahi $400 miliona ka uku mua, a me ka nui o ka huina kālā o ka hana, me kēlā ma mua, hiki aku $2.13 piliona. Ua pani ʻia ka ʻaelike.
Ua hoʻāʻo ʻia ʻo SPR2015 i nā kānaka?
ʻAʻole. Hōʻike ʻo Merck i ka SPR2015 ma ke ʻano he potent a me ke koho koho hoʻokolokolo preclinical molecular glue me ka hana antiproliferative nanomolar ma KRAS G12D-mutant cell lines. (ʻO Merck & ʻO Co. hoʻokuʻu ʻana i ka lumi nūhou, 28 Kepakemapa 2026). ʻO nā mea a pau ma lalo e pili ana i ka hoʻomaʻamaʻa ʻana a me ka hoʻolako ʻana, ʻaʻole ʻōlelo aʻo lapaʻau.
He aha nā mea e hoʻololi ai i kahi synthesis a i ʻole hoa kālailai e lawelawe ana i kahi papahana e like me kēia?
Ke neʻe mua nei ka mākaukau hoʻololi, a lilo ka mana hoʻonaʻauao i ka pou lōʻihi. ʻO kahi hoa ʻaʻole hiki ke hoʻokō i kahi hoʻokolohua ma mua o ka pono o ka mea kākoʻo e hoʻolōʻihi i ka hāʻawi holoʻokoʻa.
Ke hoʻololi nei ke kuʻikahi i ke koi no ka mana peptide synthesis?
Hoʻokahi manaʻo noiʻi mākeke e kau i ka peptide synthesis ma USD 732.58M i loko 2026, hiki i ka USD 1,438.78M e 2035 (ʻImi mua, 2026), oiai ka lua o ka manao, ma kahi ʻokoʻa, hāʻawi i ka USD 0.98B in 2026 piʻi i ka USD 1.54B e 2031 (MakekesandMarkets, 2026). Hoʻokaʻawale ka wehewehe ʻana o ka mea hoʻopuka a hiki i 3x, no laila, mai mālama i kekahi kiʻi e like me ka lawe ʻana.
Ka hopena
ʻO Merck $400 ʻOi aku ka maikaʻi o ka heluhelu ʻana o ka ʻaelike KRAS G12D ma ke ʻano he helu ʻikepili e pili ana i ka waiwai o nā waiwai mua, ʻaʻole ma ke ʻano he hoʻoholo no ka ʻāpana. ʻOi aku ka liʻiliʻi a ʻoi aku ka maʻalahi o ka hopena o ka hana: ʻO ka mākaukau hoʻoili ʻana i kēia manawa he mea e pili ana i ka hoʻoikaika ʻana i ka laikini, a ʻo nā hoa hana hiki ʻole ke hōʻike koke iā ia e hoʻolohi i kahi papahana i ka manawa kūpono loa ka wikiwiki.
Hoʻololi kēlā i nā pae loiloi e pono ai ʻoe e noi. Ka wā pōʻaiapuni, ka hoʻomaʻemaʻe ʻana i ka manawa mua e kūʻē i kahi kikoʻī i ʻōlelo ʻia, ka hoʻohālikelike ʻana i ka ʻano haumia ma waena o ka nui, ʻano-hoʻomohala hiki, ʻO nā palapala a me ka lawelawe ʻana i ka IP nā nīnau kūpono e nīnau ma mua o ke kau inoa ʻana o kahi papahana, ʻaʻole ma hope. Hoʻoholo ʻia kahi hoa hana peptide synthesis maʻalahi ma kēlā mau helu ʻeono, a pehea ka nui o nā hōʻike e paʻa nei ma mua o ka hoʻohiki ʻana.
ʻO ka nīnau e nānā i mua inā paha e lilo ka hoʻoili ʻana i nā pono hana preclinical-stage i mea paʻamau ma mua o ka ʻokoʻa. Ina pela, ʻo nā hoa i hoʻomākaukau no ia, ʻo ia ka poʻe i loaʻa mua i nā papahana.
E kamaʻilio me kahi loea loea a noi paha i kahi loiloi kūpono e ʻike i ke ʻano o ka mākaukau hoʻololi ʻana o kāu papahana e kūʻē i kēia mau pae..
